CATALYST DOSSIER · UPDATED 2026-09-22
$PEN
Unclassified · convergence — · conviction —
Price & Live Quote Loading live quote & chart…
Practice trade tools Build a reference frame, save a practice trade, or preview a draft. No brokerage order is placed.
Paper trade unavailable: missing risk-bounded frame
Reference only. Not financial advice. No brokerage order is placed.
Why $PEN?
Quantitative
Revenue (CY2026Q1) : $374.8M (+15.6% YoY)
Net Income (CY2026Q1) : $32.6M (-16.9% YoY)
Net Margin (CY2026Q2) : 8.9%
Catalysts
Multi-spoke convergence : 5 convergent signals fired: auto_macro_move_index, auto_macro_nbp_fx, auto_macro_ofr_fsi, auto_macro_options_gex, auto_macro_regime_classifier
Risks
Position-sizing discipline : Conviction AVOID (-13 score) — size accordingly; no specific catalyst-fade risk flagged
Bear case
Multiple compression : If breadth deteriorates, biotech-wide multiples re-rate lower regardless of pick-specific thesis
Sympathy basket (cerebro)
RBLX via tech r=+0.69 sympathetic (score 18)
RDDT via tech r=+0.69 sympathetic (score 17)
TU via comms r=-0.68 divergent (score 30)
VEON via comms r=-0.68 divergent (score 12)
OMH via real_estate r=-0.53 divergent (score 21)
FREI via real_estate r=-0.53 divergent (score 7)
Signals Firing
No active signals this cycle.
Earnings Catalyst No recent earnings event.
Generate full earnings report
Auto-generated from public filings + tier-1 wires. Catalyst Edge publishes its picks
and its losses — see the
trust report and
methodology .
Not financial advice. Confirm independently before trading.